RVX Insider Trading (Resverlogix)
Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): C$38,000.00
Insider Selling (Last 12 Months): C$0.00
Resverlogix Share Price & Price History
Current Price: C$0.25
Price Change: ▼ Price Decrease of -0.01 (-3.85%)
As of 06/30/2022 01:00 AM ET
A One Stop Shop for Everything Futures Trading
From RJO Futures | Ad
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
Resverlogix Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 6/27/2022 | Donald J. Mccaffrey | Director | Buy | 9,500 | C$0.25 | C$2,375.00 | 5,263,266 | |
| 6/24/2022 | Donald J. Mccaffrey | Director | Buy | 91,000 | C$0.25 | C$22,750.00 | 5,253,766 | |
| 6/22/2022 | Donald J. Mccaffrey | Director | Buy | 3,000 | C$0.25 | C$750.00 | 5,162,766 | |
| 6/16/2022 | Donald J. Mccaffrey | Director | Buy | 500 | C$0.25 | C$125.00 | 4,787,766 | |
| 6/14/2022 | Donald J. Mccaffrey | Director | Buy | 24,000 | C$0.25 | C$6,000.00 | 4,787,266 | |
| 6/14/2022 | Donald J. Mccaffrey | Director | Buy | 24,000 | C$0.25 | C$6,000.00 | 4,787,266 | |
| 8/27/2019 | Dr. Jan Ove Johansson | Senior Officer | Sell | 10,000 | C$2.89 | C$28,877.64 | 117,360 | |
| 7/9/2019 | Dr. Jan Ove Johansson | Senior Officer | Sell | 10,000 | C$3.00 | C$29,979.84 | 144,160 | |
A One Stop Shop for Everything Futures Trading
From RJO Futures | Ad
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
SEC Filings (Institutional Ownership Changes) for Resverlogix (TSE:RVX)
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.
Read More on Resverlogix
Today's Range
Now: C$0.25
52 Week Range
Now: C$0.25
Volume
181,602 shs
Average Volume
68,124 shs
Market Capitalization
C$62.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Resverlogix?
